共 50 条
- [31] Colorectal cancer trial endpoints: time for dynamic thinking?LANCET ONCOLOGY, 2016, 17 (10): : 1345 - 1347Davidson, MichaelChau, Ian
- [32] SAFETY AND EFFICACY OF REGORAFENIB IN JAPANESE PATIENTS WITH METASTATIC COLORECTAL CANCER: A SUBGROUP ANALYSIS OF THE PHASE III CORRECT TRIALANNALS OF ONCOLOGY, 2013, 24Yamada, Y.Yoshino, T.Komatsu, Y.Yamazaki, K.Tsuji, A.Ura, T.Grothey, A.Van Cutsem, E.Wagner, A.Ohtsu, A.
- [33] Regorafenib (REG) in progressive metastatic colorectal cancer (mCRC): Analysis of age subgroups in the phase III CORRECT trialJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)van Cutsem, EricSobrero, AlbertoSiena, SalvatoreFalcone, AlfredoYchou, MarcHumblet, YvesBouche, OlivierMineur, LaurentBarone, CarloAdenis, AntoineArgiles, GuillemYoshino, TakayukiLenz, Heinz-JosefGoldberg, Richard M.Sargent, Daniel J.Cihon, FrankWagner, AndreaLaurent, DirkCupit, LisaGrothey, Axel
- [34] Fluorouracil, Leucovorin, and Irinotecan Plus Either Sunitinib or Placebo in Metastatic Colorectal Cancer: A Randomized, Phase III TrialJOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (10) : 1341 - 1347Carrato, AlfredoSwieboda-Sadlej, AnnaStaszewska-Skurczynska, MarzannaLim, RobertRoman, LasloShparyk, YaroslavBondarenko, IgorJonker, Derek J.Sun, YanDe la Cruz, Jhony A.Williams, J. AndrewKorytowsky, BeataChristensen, James G.Lin, XunTursi, Jennifer M.Lechuga, Maria J.Van Cutsem, Eric
- [35] Bevacizumab plus capecitabine as maintenance treatment after initial treatment with bevacizumab plus XELOX in previously untreated metastatic colorectal cancer: Updated findings from a randomized, multicenter phase III trialJOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)Yalcin, S.Uslu, R.Dane, F.Yilmaz, U.Zengin, N.Buyukunal, E.Buyukberber, S.Camci, C.Sencan, O.Kilickap, S.
- [36] Potential Surrogate Endpoints for Prostate Cancer Survival: Analysis of a Phase III Randomized TrialJOURNAL OF THE NATIONAL CANCER INSTITUTE, 2009, 101 (04) : 228 - 236Ray, Michael E.Bae, KyounghwaHussain, Maha H. A.Hanks, Gerald E.Shipley, William U.Sandler, Howard M.
- [37] Capecitabine+3-weekly oxaliplatin (XELOX) vs. capecitabine followed by XELOX after progression as first-line treatment for patients (PTS) with metastatic colorectal cancer (MCRC): A Mexican oncology study group phase III trialANNALS OF ONCOLOGY, 2006, 17 : 120 - 120Rubio, JaimeReyes, SalvadorSoto, CeliaTorrecillas, LauraGonzalez, FernandoCastruita, AnaCabrera, PaulaCervantes, GuadalupePerez, LauraHernandez, David
- [38] Phase II clinical trial of XELOX as first line treatment for patients with unresectable or metastatic gastric cancerJOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Xu, R.Han, B.Shi, Y.Xiong, J.Li, Y.Wang, F.Qiu, M.Jiang, W.Lin, T.Zhang, L.He, Y.
- [39] PHASE 3 CORRECT TRIAL OF REGORAFENIB IN METASTATIC COLORECTAL CANCER (MCRC)ANNALS OF ONCOLOGY, 2012, 23 : 15 - 16Sobrero, AlbertoGrothey, AxelVan Cutsem, EricSiena, SalvatoreFalcone, AlfredoYchou, MarcHumblet, YvesBouche, OlivierMineur, LaurentBarone, CarloAdenis, AntoineTabernero, JosepYoshino, TakayukiLenz, Heinz JosephGoldberg, RichardSargent, DanielCihon, FrankJeffers, MichaelWagner, AndreaLaurent, Dirk
- [40] COST-UTILITY ANALYSIS OF XELOX PLUS BEVACIZUMAB VERSUS XELOX FOR METASTATIC COLORECTAL CANCER TREATMENT IN THAILANDVALUE IN HEALTH, 2022, 25 (12) : S53 - S53Wanitphisitphan, C.Kositamongkol, C.Korphaisarn, K.Akewanlop, C.Srimuninnimit, VPhisalprapa, P.